{"protocolSection":{"identificationModule":{"nctId":"NCT03252626","orgStudyIdInfo":{"id":"SEAAIS"},"organization":{"fullName":"The First Hospital of Jilin University","class":"OTHER"},"briefTitle":"Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke","officialTitle":"Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2021-08","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-08-18","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2022-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2017-08-08","studyFirstSubmitQcDate":"2017-08-15","studyFirstPostDateStruct":{"date":"2017-08-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-10-12","lastUpdatePostDateStruct":{"date":"2021-10-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"The First Hospital of Jilin University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Ischemic stroke has a variety of treatments and currently drug therapy is one of the main treatments.A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of significant dilation of blood vessels, inhibition of plate aggregation, anti-atherosclerosis and increased cerebral blood flow.Evaluate the 90-days efficacy by comparing two groups of patients'(one with alprostadil,another with placebo) mRS."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":950,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Alprostadil","type":"ACTIVE_COMPARATOR","description":"Based on the standard medical care, 2ml of Alprostadil","interventionNames":["Drug: Alprostadil"]},{"label":"Normal saline","type":"PLACEBO_COMPARATOR","description":"Based on the standard medical care, 2ml of 0.9% saline as the placebo","interventionNames":["Drug: Normal saline"]}],"interventions":[{"type":"DRUG","name":"Alprostadil","description":"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.\n\n2ml Alprostadil injection added into 10ml 0.9% saline.","armGroupLabels":["Alprostadil"]},{"type":"DRUG","name":"Normal saline","description":"2ml normal saline injection added into 10ml 0.9% saline.","armGroupLabels":["Normal saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Rankin Scale at Day 90","timeFrame":"day 90"}],"secondaryOutcomes":[{"measure":"Incidence of major vascular events in 30 or 90 days including ischemic stroke and hemorrhagic stroke","description":"Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.","timeFrame":"day 30, day 90"},{"measure":"Incidence of stroke events in 30 or 90 days including ischemic stroke and hemorrhagic stroke","timeFrame":"day 30, day 90"},{"measure":"Barthel Index score","description":"compared the changes in activities of daily living (Barthel index) between the two groups","timeFrame":"day 30, day 90"},{"measure":"EQ-5D scale","description":"compared the changes in EQ-5D scale","timeFrame":"day 30, day 90"},{"measure":"Documentation of adverse events (AEs)","description":"compared the rates of adverse events","timeFrame":"day 30, day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. ischemic stroke diagnosed by CT or MRI\n2. Age: 18-75 years\n3. Pre-stroke mRS score is 0-1\n4. within 72 hours symptoms onset\n5. 4 â‰¤ NIHSS \\<20\n6. Patient is willing to participate voluntarily and to sign a written patient informed consent\n\nExclusion Criteria:\n\n1. intracranial tumors, encephalitis or lesions diagnosed by CT or MRI\n2. patients with thrombolytic therapy\n3. low platelet , blood system diseases or other bleeding tendency\n4. suspected subarachnoid hemorrhage or aortic dissection coma\n5. atrial fibrillation, myocardial infarction, heart valve disease, infective endocarditis, heart rate \\<50 beats / min\n6. ALT or AST continued to rise more than 3 times the upper limit of normal creatinine clearance rate\\<30ml/min\n7. Dementia and mental illness\n8. Patient who is participating in other trials or has been participated in other trials in recent 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000000527","term":"Alprostadil"}],"ancestors":[{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000014665","term":"Vasodilator Agents"},{"id":"D000064804","term":"Urological Agents"}],"browseLeaves":[{"id":"M3558","name":"Alprostadil","asFound":"Tylenol","relevance":"HIGH"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M17102","name":"Vasodilator Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"VaDiAg","name":"Vasodilator Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"Urol","name":"Urological Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}